In a report released yesterday, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Dermira (DERM), with a price target of $20. The company’s shares closed yesterday at $11.61.
Chen noted:
“We reiterate our OW rating. DERM is a leading dermatology company with commercial and pipeline advancements that could drive upward earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.3% and a 40.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Dermira is a Strong Buy with an average price target of $18.50, a 59.3% upside from current levels. In a report issued on November 19, Guggenheim also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.42 and a one-year low of $6.98. Currently, Dermira has an average volume of 552.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.
